Omzotirome

DB16046InvestigationalSmall molecule

TRC150094 is under investigation in clinical trial NCT03254446 (Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension).

Mechanism: Pharmacologically active on Thyroid hormone receptor
Curator reviewed
Formula / weight: C₁₉H₂₄N₂O₃ · 328.412 g/mol (avg)
Code names: TRC-150094

Resolves to

Compound

UNIIB93608MTGWCAS1092551-88-6ChEMBLCHEMBL4297445

Structure

InChIKeyOFUOCIUIWKDKPA-UHFFFAOYSA-NSMILESCC1=NN(CCC(O)=O)C(C)=C1CC1=CC(C)=C(O)C2=C1CCC2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Omzotirome, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account